Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Biotech Stock News: Novavax (Nasdaq: $NVAX) Provides Phase 3 COVID-19 Vaccine Clinical Development Update
GAITHERSBURG, Md. - October 28, 2020 (Investorideas.com Newswire) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate.

PR-Combined Market Cap of Five Largest MedTech Companies Surged by $40bn YoY
October 28, 2020 (Investorideas.com Newswire) The coronavirus outbreak put immense pressure on the healthcare industry, forcing pharmaceutical institutions to roll out clinical trials for a COVID-19 vaccine at breakneck speed.

Health and Wellness Stock News: BioHarvest Sciences Inc. (CSE: BHSC) Appoints World Renowned Medical Physician and Nutritionist to Company Advisory Board
Vancouver, British Columbia - October 23, 2020 (Newsfile Corp.) (Investorideas.com Newswire) BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") announces that it has added Dr. David Brady as a member of its Advisory Board.

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial
October 22, 2020 (Investorideas.com Newswire) Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder.

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury
October 21, 2020 (Investorideas.com Newswire) Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co.

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals
October 20, 2020 (Investorideas.com Newswire) Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction.

Trending Stock News: BOQI International Medical Inc. (NASDAQ: $BIMI) Announces Second Quarter 2020 Financial Results, Revenue increased by 1026% Over the Same Period Last Year
NEW YORK - October 19, 2020 (Investorideas.com Newswire) Investorideas.com reports on trending stock news for Monday October 19th - BOQI International Medical Inc. (NASDAQ: BIMI) ("BIMI" or the "Company") today announced its financial results for the second quarter and six months ended June 30, 2020.

Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion
October 15, 2020 (Investorideas.com Newswire) Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion.

Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment
October 15, 2020 (Investorideas.com Newswire) The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report.

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate
October 14, 2020 (Investorideas.com Newswire) Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Sponsored Financial Content and Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

Media Central Sets Date for Special Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - October 29, 2020) -  Media Central Corporation Inc. (CSE: FLYY) (FSE: 3AT) ("Media Central" or the "Company") announces the date for a Special Meeting of Shareholders (the "Meeting") as December 30, 2020. Following receipt of a shareholder requisition for a special meeting (See press release dated October 15, 2020), the Company has directed its transfer agent to file a Notice of Record and Meeting Dates with the relevant regulators and...

PreveCeutical Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2020) -  PreveCeutical Medical Inc.  (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been granted an extension of six months by the Registrar of Companies, to hold its Annual General Meeting ("AGM")for the year 2020 under section 182(4) of the Business Corporations Act. The six months extension is from October 29, 2020, to April 29, 2021.With the challenges related to COVID-19,...

Enablence Announces Delay of Annual Financial Information for the Year Ended June 30, 2020
Ottawa, Ontario--(Newsfile Corp. - October 28, 2020) - Enablence Technologies Inc. (TSXV: ENA) ("Enablence" or the "Company"), a leading supplier of optical components and subsystems, today announces that its audited annual financial statements and accompanying management discussion and analysis for the year ended June 30, 2020 (the "Fiscal 2020 Annual Financial Information") will be delayed. On September 25, 2020, the Company filed amended and restated audited annual financial statements for the years ended...

Nextleaf Solutions Granted 50th Patent and Provides Commercial Update
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf", "OILS", or the "Company"), Canada's most innovative cannabis extractor, is pleased to provide shareholders with the following commercial update:Vape Cartridges Powered by OILSTM now Available in the Provincial Retail MarketVape cartridges powered by OILS high purity distillate are available at cannabis retailers in the Saskatchewan adult-use market, with more provinces to be announced in the coming months....

BioVaxys and The Ohio State University Enter into SARS-CoV-2 Research Collaboration to Study New Vaccine
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University ("OSU") for BioVaxys' SARS-CoV-2 vaccine candidate. OSU is a leading global academic research institute in the fight against SARS-CoV-2, with The Ohio State University Wexner Medical Center ("OSUWMC") also recently selected as a site for SARS2 multicenter clinical trials.The objective...

Subscribe to Biotech News